Agile Therapeutics, Inc.
AGRX · NASDAQ
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
|---|---|---|---|---|
| Market Cap | $10 | $1 | $6 | $7 |
| - Cash | $3 | $3 | $3 | $3 |
| + Debt | $0 | $0 | $2 | $3 |
| Enterprise Value | $7 | -$1 | $5 | $7 |
| Revenue | $6 | $6 | $4 | $7 |
| % Growth | -2.4% | 58.2% | -45.8% | – |
| Gross Profit | $4 | $4 | $1 | $4 |
| % Margin | 73.2% | 70.6% | 39.4% | 62.8% |
| EBITDA | -$3 | $2 | -$4 | -$0 |
| % Margin | -49.2% | 27.5% | -112.5% | -5.4% |
| Net Income | -$12 | $1 | -$4 | -$1 |
| % Margin | -212.9% | 22.5% | -123.7% | -12% |
| EPS Diluted | -1.73 | 0.28 | -1.51 | -0.27 |
| % Growth | -717.9% | 118.5% | -459.3% | – |
| Operating Cash Flow | $0 | -$2 | $0 | $0 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | $0 | -$2 | $0 | $0 |